News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. equities slipped with consumer sectors weighing while energy and select chip names outperformed, lifting volatility.
  • Micron named Deirdre Hanford president of its $10 billion Micron Research Labs to advance memory, compute and AI technology development.
  • Telesat signed a global deal with SatPort to build Lightspeed ground stations, expanding low-latency broadband for enterprise and government customers.
  • Expand Energy priced $500 million of 5.65% senior notes due 2031 to fund general corporate purposes.
  • Beta Bionics launched a proposed $125 million common stock offering to fund commercialization of its Mint automated insulin-delivery system.
  • FTAI Aviation authorized up to $500 million in share repurchases through 2029 to support its capital structure.

Latest Articles

Euronet Worldwide Reports Second Quarter 2026 Financial Results

Euronet Worldwide Reports Second Quarter 2026 Financial Results

Euronet Worldwide announced its second quarter 2026 financial results, highlighting a 3% revenue increase to $1.108 billion and a 10% increase in adjusted earnings per share to $2.82. The company demonstrated strong growth in its digital accelerator revenue, which increased 31% year over year and represented 26% of total revenues. Strategic initiat…

Immutep Quarterly Activities Report Q4 FY26

Immutep Quarterly Activities Report Q4 FY26

Immutep Limited provided its Q4 FY26 activities update, highlighting positive pooled analysis results from efti trials demonstrating a 7.7-month median overall survival benefit in responders across multiple cancers. However, the Phase III TACTI-004 trial in first-line NSCLC was discontinued due to futility. Encouraging Phase I results were presente…

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

Iovance Biotherapeutics, a biotechnology firm specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer, will report its Q2 2026 financial results and corporate updates on August 6, 2026. The company is a leader in TIL therapy innovation, with its Amtagvi® therapy approved by the FDA for solid tumors. The webcast aims to provide inve…

ASP Isotopes to Participate in Canaccord Genuity’s 46th Annual Growth Conference on August 12, 2026

ASP Isotopes to Participate in Canaccord Genuity’s 46th Annual Growth Conference on August 12, 2026

ASP Isotopes Inc. announced that its Chief Commercial Officer will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company focuses on advanced isotope enrichment technologies for critical materials in sectors such as nuclear medicine, semiconductors, and nuclear energy. Additionally, ASP Isotopes is involved i…

ZenaTech's DaaS Oil and Gas Business Enters a Strengthened Market with Higher Oil Prices and More Than US$500 Billion in Expected Canadian Energy Investment Over the Next Decade

ZenaTech's DaaS Oil and Gas Business Enters a Strengthened Market with Higher Oil Prices and More Than US$500 Billion in Expected Canadian Energy Investment Over the Next Decade

ZenaTech, Inc. announced the acquisition of Velocity Geomatics, a drone-based surveying and regulatory compliance service provider for the oil and gas sector in Western Canada. This move expands ZenaTech's Drone as a Service (DaaS) business amid a favorable market, supported by a 45% year-over-year increase in crude oil prices and over $500 billion…

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Aprea Therapeutics updates clinical progress on APR-1051, its oral WEE1 inhibitor, reporting accelerated enrollment and plans to expand development into combination regimens for multiple biomarker-defined cancers. The company anticipates presenting new Phase 1 data from ACESOT-1051 in Q4 2026, supporting further dose escalation and development in u…

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Verrica Pharmaceuticals will report its second quarter 2026 financial results on August 6, 2026, and provide a corporate update via conference call and webcast. The company focuses on dermatological disease treatments, including FDA-approved YCANTH® for molluscum contagiosum and pipeline products targeting common warts and non-melanoma skin cancers…

Uniti Group Inc. Reports Second Quarter 2026 Results

Uniti Group Inc. Reports Second Quarter 2026 Results

Uniti Group Inc. announced its second quarter 2026 financial results, highlighting record new bookings at its Fiber Infrastructure segment and strong growth in Kinetic Consumer Fiber revenue and subscriber base. The company updated its full-year 2026 outlook with consolidated revenue expected between $3.63 billion and $3.68 billion, and adjusted EB…

Stride Announces CEO Succession

Stride Announces CEO Succession

Stride, Inc. announced the appointment of Robert Knowling as CEO succeeding James Rhyu, and named Steven Fink as Chair of the Board. Brian Shepherd joins the board to strengthen leadership amid a focus on growth and innovation. The company reported strong preliminary fiscal year 2026 financial results with increases in revenue, operating income, an…

Aduro Secures Uinta Basin Crude Supply and Completes Continuous-Flow Unit, Advancing Paraffinic Crude Program to Technology Demonstration

Aduro Secures Uinta Basin Crude Supply and Completes Continuous-Flow Unit, Advancing Paraffinic Crude Program to Technology Demonstration

Aduro Clean Technologies has made significant progress in its paraffinic crude program by securing yellow and black paraffinic crude feedstocks from Uinta Basin sources and completing a new lab-scale continuous-flow unit. The expansion and consolidation of its London facility support ongoing Technology Demonstration stages aimed at improving proces…

Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

Anavex Life Sciences Corp. announced preliminary financial results for Q2 2026, showing reduced net loss and increased cash resources supporting operations into 2028. The company is prioritizing its lead compound blarcamesine (ANAVEX®2-73) across three CNS indications: early Alzheimer's disease, Rett syndrome, and Fragile X syndrome, and is engagin…

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

Enlivex Ltd., a Nasdaq-listed company, announced a significant surge in trading volume on its Rain protocol, reaching $860 million in July 2026, representing a 622% month-over-month increase from June. The company expects the Rain protocol's trading volumes to grow exponentially in the coming years, forecasted to reach $33 billion by 2029, driving …

Innventure to Announce Second Quarter 2026 Results on August 13, 2026

Innventure to Announce Second Quarter 2026 Results on August 13, 2026

Innventure, Inc., an industrial growth conglomerate listed on NASDAQ under the ticker INV, announced it will release its Q2 2026 financial results on August 13, 2026. The release will be followed by a conference call including remarks from the incoming CEO Dr. Bill Grieco and CEO of Accelsius, John Hewitt. The company focuses on building scalable i…

Gentherm Announces Participation in J.P. Morgan Auto Conference and Seaport Annual Summer Investor Conference

Gentherm Announces Participation in J.P. Morgan Auto Conference and Seaport Annual Summer Investor Conference

Gentherm, a leader in thermal management and pneumatic comfort technologies, announced its participation in two upcoming investor conferences, including a fireside chat at the J.P. Morgan Auto Conference and hosting investors at the Seaport Annual Summer Investor Conference. The events aim to provide insights into the company's performance and outl…

Aureus Greenway Holdings Inc. and Autonomous Power Corporation (dba Powerus) Announce Public Filing of Form S-4 Registration Statement with the SEC

Aureus Greenway Holdings Inc. and Autonomous Power Corporation (dba Powerus) Announce Public Filing of Form S-4 Registration Statement with the SEC

Aureus Greenway Holdings Inc. (Nasdaq: PUSA) has filed a Form S-4 registration statement with the SEC as part of its proposed business combination with Autonomous Power Corporation (dba Powerus). The merger aims to position the combined entity as a leader in domestically produced defense autonomy and counter-drone technology. The combined company w…

Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy

Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy

Nuwellis, Inc. announced acceptance of a retrospective study in Frontiers in Pediatrics demonstrating that epoprostenol is a safe and feasible alternative anticoagulant for Aquadex ultrafiltration therapy in critically ill pediatric patients. This supports broader adoption of Aquadex therapy and offers clinicians an additional tool for complicated …